Catalog No.
DHB95501
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
IL1F1, Interleukin-1 alpha, IL1A, Hematopoietin-1, IL-1 alpha
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01583
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MABp1, Xilonix-, CAS: 1401965-15-8
Clone ID
Bermekimab
Note
For research use only. Not suitable for clinical or therapeutic use.
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer., PMID:25822109
A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous revascularization., PMID:26433546
Targeting IL-1α in cancer cachexia: a narrative review., PMID:30300155
Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer., PMID:30723583
Pharmacological development in hidradenitis suppurativa., PMID:31075754
Systematic review of immunomodulatory therapies for hidradenitis suppurativa., PMID:31190730
A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain., PMID:32004568
Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases., PMID:33482337
Efficacy of non-surgical monotherapies for hidradenitis suppurativa: a systematic review and network meta-analyses of randomized trials., PMID:33961535
Target molecules for future hidradenitis suppurativa treatment., PMID:34085329
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa., PMID:34283386
Transport study of interleukin-1 inhibitors using a human in vitro model of the blood-brain barrier., PMID:34589799
New and Emerging Targeted Therapies for Hidradenitis Suppurativa., PMID:35409118
Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders., PMID:35874710
IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications., PMID:36012744
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma., PMID:36056179
Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma., PMID:36333397
Computational Drug Discovery in Ankylosing Spondylitis-Induced Osteoporosis Based on Data Mining and Bioinformatics Analysis., PMID:36716856
A randomized clinical trial of bermekimab treatment for clinical improvement of systemic sclerosis., PMID:37680472
An overview of new and emerging antibody therapies for moderate-severe atopic dermatitis in adults., PMID:38054328
Therapeutic Potential of IL-1 Antagonism in Hidradenitis Suppurativa., PMID:38397412
Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies., PMID:39214920
Report of successful treatment of follicular occlusion triad with adalimumab and research progress on biologic therapy for follicular occlusion triad., PMID:39251215
The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials., PMID:40268126
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer, PMID: 25822109
Targeting IL-1α in cancer cachexia: a narrative review, PMID: 30300155
Target molecules for future hidradenitis suppurativa treatment, PMID: 34085329
Systematic review of immunomodulatory therapies for hidradenitis suppurativa, PMID: 31190730
Pharmacological development in hidradenitis suppurativa, PMID: 31075754
Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer, PMID: 30723583
Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases, PMID: 33482337
Efficacy of non-surgical monotherapies for hidradenitis suppurativa: a systematic review and network meta-analyses of randomized trials, PMID: 33961535
A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous revascularization, PMID: 26433546
A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain, PMID: 32004568
For research use only. Not for human or drug use.
